Phibro Animal Health (PAHC) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

PAHC Stock Forecast


Phibro Animal Health stock forecast is as follows: an average price target of $18.67 (represents a -13.92% downside from PAHC’s last price of $21.69) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

PAHC Price Target


The average price target for Phibro Animal Health (PAHC) is $18.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $17.00. This represents a potential -13.92% downside from PAHC's last price of $21.69.

PAHC Analyst Ratings


Buy

According to 3 Wall Street analysts, Phibro Animal Health's rating consensus is 'Buy'. The analyst rating breakdown for PAHC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 1 'Hold' (33.33%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).

Phibro Animal Health Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 21, 2022Roth Capital$18.00$12.7541.18%-17.01%
Sep 16, 2022Barclays$17.00$14.2918.96%-21.62%
Aug 26, 2022Morgan Stanley$21.00$16.0630.76%-3.18%

The latest Phibro Animal Health stock forecast, released on Dec 21, 2022 by Roth Capital company, set a price target of $18.00, which represents a 41.18% increase from the stock price at the time of the forecast ($12.75), and a -17.01% decrease from PAHC last price ($21.69).

Phibro Animal Health Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$21.69$21.69$21.69
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Phibro Animal Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Phibro Animal Health's last price of $21.69. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 10, 2024BarclaysUnderweightUnderweightHold
Dec 21, 2022Roth CapitalBuyInitialise
Sep 16, 2022BarclaysUnderweightUnderweightHold
Aug 26, 2022Morgan StanleyEqual-WeightEqual-WeightHold

Phibro Animal Health's last stock rating was published by Barclays on May 10, 2024. The company gave PAHC a "Underweight" rating, the same as its previous rate.

Phibro Animal Health Financial Forecast


Phibro Animal Health Revenue Forecast

Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Revenue----------$249.94M$231.30M$255.05M$245.70M$244.65M$232.52M$255.30M$239.62M$232.71M$214.66M$220.28M$211.73M$206.15M$195.19M$185.88M$210.74M$214.01M$189.72M$203.88M$205.74M
Avg Forecast$289.62M$285.26M$280.96M$276.73M$316.52M$309.50M$292.26M$246.70M$260.49M$253.65M$240.93M$242.00M$256.13M$246.69M$241.29M$232.09M$250.04M$230.53M$215.28M$201.06M$214.28M$208.06M$205.48M$189.08M$191.20M$207.45M$218.87M$199.38M$206.00M$214.94M
High Forecast$309.32M$304.66M$300.07M$295.55M$338.04M$376.22M$350.50M$263.47M$278.20M$253.65M$247.14M$258.46M$273.55M$263.47M$257.70M$232.09M$250.04M$230.53M$215.28M$201.06M$214.28M$208.06M$205.48M$189.08M$191.20M$207.45M$218.87M$199.38M$206.00M$214.94M
Low Forecast$279.51M$275.30M$271.15M$267.07M$305.46M$275.25M$262.29M$238.08M$251.39M$253.65M$237.18M$233.55M$247.19M$238.08M$232.86M$232.09M$250.04M$230.53M$215.28M$201.06M$214.28M$208.06M$205.48M$189.08M$191.20M$207.45M$218.87M$199.38M$206.00M$214.94M
# Analysts111112211131111111111119998888
Surprise %----------1.04%0.96%1.00%1.00%1.01%1.00%1.02%1.04%1.08%1.07%1.03%1.02%1.00%1.03%0.97%1.02%0.98%0.95%0.99%0.96%

Phibro Animal Health's average Quarter revenue forecast for Mar 24 based on 1 analysts is $253.65M, with a low forecast of $253.65M, and a high forecast of $253.65M. PAHC's average Quarter revenue forecast represents a 1.48% increase compared to the company's last Quarter revenue of $249.94M (Dec 23).

Phibro Animal Health EBITDA Forecast

Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts111112211131111111111119998888
EBITDA----------$15.70M$-700.00K$33.08M$18.60M$24.91M$22.61M$22.90M$27.68M$34.49M$20.37M$27.00M$28.78M$27.40M$27.43M$26.84M$30.57M$28.98M$15.19M$19.92M$29.81M
Avg Forecast$32.62M$32.13M$31.65M$31.17M$35.65M$34.86M$32.92M$27.79M$29.34M$48.92M$27.14M$27.26M$28.85M$44.47M$40.93M$21.72M$23.40M$40.43M$20.15M$18.82M$20.06M$28.78M$19.23M$17.70M$17.90M$26.98M$20.49M$18.66M$19.28M$32.58M
High Forecast$34.84M$34.32M$33.80M$33.29M$38.08M$42.38M$39.48M$29.68M$31.34M$58.70M$27.84M$29.11M$30.81M$53.37M$49.11M$21.72M$23.40M$48.51M$20.15M$18.82M$20.06M$34.54M$19.23M$17.70M$17.90M$32.37M$20.49M$18.66M$19.28M$39.10M
Low Forecast$31.48M$31.01M$30.54M$30.08M$34.41M$31.00M$29.54M$26.82M$28.32M$39.13M$26.72M$26.31M$27.84M$35.58M$32.74M$21.72M$23.40M$32.34M$20.15M$18.82M$20.06M$23.02M$19.23M$17.70M$17.90M$21.58M$20.49M$18.66M$19.28M$26.07M
Surprise %----------0.58%-0.03%1.15%0.42%0.61%1.04%0.98%0.68%1.71%1.08%1.35%1.00%1.42%1.55%1.50%1.13%1.41%0.81%1.03%0.91%

1 analysts predict PAHC's average Quarter EBITDA for Mar 24 to be $48.92M, with a high of $58.70M and a low of $39.13M. This is 211.56% upper than Phibro Animal Health's previous annual EBITDA (Dec 23) of $15.70M.

Phibro Animal Health Net Income Forecast

Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts111112211131111111111119998888
Net Income----------$1.27M$-8.00M$11.50M$10.00M$7.21M$3.86M$7.50M$17.69M$17.46M$6.53M$17.12M$12.16M$12.80M$12.30M$5.64M$13.50M$11.89M$2.52M$8.80M$14.85M
Avg Forecast$23.13M$22.32M$21.31M$14.00M$18.26M$17.35M$17.25M$10.06M$13.53M$22.63M$11.36M$9.33M$15.12M$20.57M$16.88M$10.69M$15.29M$18.70M$13.30M$11.91M$12.69M$12.16M$11.37M$8.18M$9.34M$11.91M$11.61M$9.83M$14.70M$16.23M
High Forecast$25.18M$24.29M$23.19M$15.24M$19.88M$22.12M$20.19M$10.95M$13.53M$27.15M$13.47M$11.36M$16.45M$24.68M$20.26M$10.69M$15.29M$22.44M$13.30M$11.91M$12.69M$14.59M$11.37M$8.18M$9.34M$14.30M$11.61M$9.83M$14.70M$19.48M
Low Forecast$22.08M$21.31M$20.34M$13.37M$17.43M$14.75M$14.30M$9.61M$13.52M$18.10M$10.10M$8.12M$14.43M$16.46M$13.51M$10.69M$15.29M$14.96M$13.30M$11.91M$12.69M$9.73M$11.37M$8.18M$9.34M$9.53M$11.61M$9.83M$14.70M$12.98M
Surprise %----------0.11%-0.86%0.76%0.49%0.43%0.36%0.49%0.95%1.31%0.55%1.35%1.00%1.13%1.50%0.60%1.13%1.02%0.26%0.60%0.91%

Phibro Animal Health's average Quarter net income forecast for Mar 24 is $22.63M, with a range of $18.10M to $27.15M. PAHC's average Quarter net income forecast represents a 1676.04% increase compared to the company's last Quarter net income of $1.27M (Dec 23).

Phibro Animal Health SG&A Forecast

Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts111112211131111111111119998888
SG&A----------$62.91M$68.50M$52.90M$57.00M$61.54M$54.96M$55.50M$52.43M$48.38M$50.07M$50.67M$49.03M$48.38M$48.43M$42.45M$48.23M$49.49M$47.52M$53.20M$42.30M
Avg Forecast$65.91M$64.92M$63.94M$62.98M$72.03M$70.44M$66.51M$56.14M$59.28M$67.07M$54.83M$55.07M$58.29M$60.97M$46.77M$52.82M$56.90M$55.43M$48.99M$45.76M$48.76M$49.03M$46.76M$43.03M$43.51M$42.56M$49.81M$45.37M$46.88M$46.24M
High Forecast$70.39M$69.33M$68.29M$67.26M$76.93M$85.62M$79.76M$59.96M$63.31M$80.48M$56.24M$58.82M$62.25M$73.17M$56.12M$52.82M$56.90M$66.51M$48.99M$45.76M$48.76M$58.84M$46.76M$43.03M$43.51M$51.07M$49.81M$45.37M$46.88M$55.49M
Low Forecast$63.61M$62.65M$61.71M$60.78M$69.52M$62.64M$59.69M$54.18M$57.21M$53.65M$53.98M$53.15M$56.25M$48.78M$37.41M$52.82M$56.90M$44.34M$48.99M$45.76M$48.76M$39.23M$46.76M$43.03M$43.51M$34.05M$49.81M$45.37M$46.88M$36.99M
Surprise %----------1.15%1.24%0.91%0.93%1.32%1.04%0.98%0.95%0.99%1.09%1.04%1.00%1.03%1.13%0.98%1.13%0.99%1.05%1.13%0.91%

Phibro Animal Health's average Quarter SG&A projection for Mar 24 is $67.07M, based on 1 Wall Street analysts, with a range of $53.65M to $80.48M. The forecast indicates a 6.60% rise compared to PAHC last annual SG&A of $62.91M (Dec 23).

Phibro Animal Health EPS Forecast

Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts111112211131111111111119998888
EPS----------$0.03$-0.20-$0.25$0.18$0.10$0.18$0.44$0.43$0.16$0.42$0.30$0.32$0.30$0.14$0.33$0.29$0.06$0.22$0.37
Avg Forecast$0.57$0.55$0.53$0.34$0.45$0.43$0.42$0.25$0.33$0.29$0.28$0.23$0.37$0.34$0.30$0.26$0.38$0.35$0.33$0.29$0.31$0.35$0.28$0.20$0.23$0.34$0.29$0.24$0.36$0.43
High Forecast$0.62$0.60$0.57$0.38$0.49$0.55$0.50$0.27$0.33$0.32$0.33$0.28$0.41$0.36$0.33$0.26$0.38$0.35$0.33$0.29$0.31$0.35$0.28$0.20$0.23$0.34$0.29$0.24$0.36$0.43
Low Forecast$0.54$0.53$0.50$0.33$0.43$0.36$0.35$0.24$0.33$0.28$0.25$0.20$0.36$0.32$0.29$0.26$0.38$0.35$0.33$0.29$0.31$0.35$0.28$0.20$0.23$0.34$0.29$0.24$0.36$0.43
Surprise %----------0.11%-0.87%-0.75%0.60%0.38%0.48%1.25%1.31%0.55%1.34%0.86%1.14%1.49%0.61%0.97%1.01%0.25%0.61%0.86%

According to 1 Wall Street analysts, Phibro Animal Health's projected average Quarter EPS for Mar 24 is $0.29, with a low estimate of $0.28 and a high estimate of $0.32. This represents a 820.63% increase compared to PAHC previous annual EPS of $0.03 (Dec 23).

Phibro Animal Health Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PROCProcaps Group$3.69$10.00171.00%
ANIPANI Pharmaceuticals$55.83$79.0041.50%Buy
COLLCollegium Pharmaceutical$30.90$42.3336.99%Buy
PCRXPacira BioSciences$19.83$23.7519.77%Hold
PBHPrestige Consumer Healthcare$80.39$89.5011.33%Buy
PAHCPhibro Animal Health$22.34$18.67-16.43%Buy

PAHC Forecast FAQ


Is Phibro Animal Health a good buy?

Yes, according to 3 Wall Street analysts, Phibro Animal Health (PAHC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of PAHC's total ratings.

What is PAHC's price target?

Phibro Animal Health (PAHC) average price target is $18.67 with a range of $17 to $21, implying a -13.92% from its last price of $21.69. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Phibro Animal Health stock go up soon?

According to Wall Street analysts' prediction for PAHC stock, the company can go down by -13.92% (from the last price of $21.69 to the average price target of $18.67), down by -3.18% based on the highest stock price target, and down by -21.62% based on the lowest stock price target.

Can Phibro Animal Health stock reach $30?

PAHC's average twelve months analyst stock price target of $18.67 does not support the claim that Phibro Animal Health can reach $30 in the near future.

What are Phibro Animal Health's analysts' financial forecasts?

Phibro Animal Health's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $1.16B (high $1.33B, low $1.08B), average EBITDA is $131.22M (high $149.61M, low $121.77M), average net income is $62.92M (high $73.14M, low $56.09M), average SG&A $265.12M (high $302.27M, low $246.03M), and average EPS is $1.55 (high $1.8, low $1.38). PAHC's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $1.13B (high $1.21B, low $1.09B), average EBITDA is $127.57M (high $136.25M, low $123.12M), average net income is $80.76M (high $87.9M, low $77.09M), average SG&A $257.75M (high $275.28M, low $248.75M), and average EPS is $1.99 (high $2.17, low $1.9).

Did the PAHC's actual financial results beat the analysts' financial forecasts?

Based on Phibro Animal Health's last annual report (Jun 2023), the company's revenue was $977.89M, beating the average analysts forecast of $976.2M by 0.17%. Apple's EBITDA was $108.49M, missing the average prediction of $135.97M by -20.21%. The company's net income was $32.61M, missing the average estimation of $63.26M by -48.46%. Apple's SG&A was $226.39M, beating the average forecast of $218.84M by 3.45%. Lastly, the company's EPS was $0.81, missing the average prediction of $1.27 by -36.39%. In terms of the last quarterly report (Dec 2023), Phibro Animal Health's revenue was $249.94M, beating the average analysts' forecast of $240.93M by 3.74%. The company's EBITDA was $15.7M, missing the average prediction of $27.14M by -42.14%. Phibro Animal Health's net income was $1.27M, missing the average estimation of $11.36M by -88.79%. The company's SG&A was $62.92M, beating the average forecast of $54.83M by 14.75%. Lastly, the company's EPS was $0.0315, missing the average prediction of $0.28 by -88.75%